reason report
solid hiv futur outlook depend event
bottom line gilead top bottom line beat encourag
sign stabil revenu still declin sober yoy
although vs hiv busi grew yoy
sequenti newer combin launch off-set eros
legaci combin still hurdl ahead gilead
includ generic letairi ranexa compani
futur much depend continu perform hiv
portfolio perform mid late stage pivot trial jak
inhibitor filgotinib array medicin develop nash
worryingli gilead oncolog cornerston yescarta face growth
challeng complic dose slow hospit uptak filgotinib
may delay us launch compar consensu expect
increas near-term revenu estim
pro forma ep estim given quarterli momentum
reduc estim onward base slower
trajectori filgotinib continu eros legaci product hcv
program base chang peer compani multipl reduc
price target reiter market perform rate
revenu due hiv out-performance total revenu
consensu line estim
total hiv product sale street expect
estim hiv sale grew sequenti
boost strong biktarvi launch strong genvoya sale
continu growth truvada prep segment impact
gener european countri signific
expect year total hcv sale line
consensu estim reflect declin
patient treat gilead hcv medicin sale non-antivir
product primarili boost letairi expect
declin due presum gener introduct quarter howev
manag disclos single-shar rem letairi gener
requir launch yet approv timelin
fda action result gilead expect letairi revenu remain
flat least anoth quarter although eros would still seem like
sometim
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
ep driven lighter expens lower tax rate
gilead product gross margin line consensu
prior quarter non-gaap
consensu forecast non-gaap
sg consensu estim
oper margin appear stabil rang
although expect pressur hcv sale declin new
effect tax rate consensu
estim contribut materi ep beat
modest guidanc boost captur less gener eros
lower tax gilead increas previous issu top-lin financi
guidanc increas
result slower anticip gener eros tdf-base
hiv regimen europ well increas letairi expect
due delay gener launch expens gilead continu
expect non-gaap sg expens
gross margin guidanc howev
compani expect full-year tax rate
rate gilead stock market perform price target downgrad stock
sept chang hepat market forecast compani
continu erod sharpli sooner anticip specif see
patient volum declin steadili initi peak market revenu yield per
patient continu trend neg base decreas treatment durat increas
discount manufactur compet govern commerci contract posit
forecast hcv sale declin continu eros subsequ year due
competit market dynam outlook compani hiv busi remain posit
suffici off-set unusu dynam hcv busi rel
modest contribut product offer littl mitig effect boom bust
hcv forecast total hcv revenu fall short current consensu
like drive signific neg margin trend given hcv extrem strong profit
hope gilead intern develop pipelin busi develop invest could
off-set risk opportun appear arriv late littl valu
high price gilead manag miss sever attract transact opportun
paid high premium enter oncolog market cellular therapi without declar
competit advantag gilead valuat like recov rel peer earn declin
potenti continu neg revis substanti termin uncertainti
make hard us recommend stock
balanc capit alloc trend continu gilead finish approxim
cash debt balanc sheet net cash gilead report oper
cash flow tax-adjust ad back therefor gilead spend
estim adjust cash flow invest dividend
share repurchas expect trend toward balanc capit alloc continu
unless compani new manag tbd decid take risk prior
administr ambit
includ sever pivot trial readout develop mileston gilead
manag provid usual comprehens pipelin updat confer call
believ two major catalyst compani stock within next month first
gilead releas import result compani nash program two separ
monotherapi phase studi selonsertib inhibitor trial fulli enrol
fibrosi patient read respect assum
success gilead plan file simultan two studi
close togeth would effect first diseas modifi fibrosis-revers treatment
approv indic would expect launch trajectori slow investor
would like give compani consider credit long term potenti
second two final rheumatoid arthriti trial trial gilead filgotinib
also readout could valid claim best-in-class product
categori unfortun appear gilead need wait anoth trial matur
recruit run file applic filgotinib enrol
week phase ii manta safeti studi men ulcer coliti primarili show drug
safeti lack effect spermatogenesi studi schedul complet late
best circumst ulcer coliti trial prove difficult
enrol warn patient consent risk decreas sperm count
oblig regularli provid sampl measur may weigh enrol
gilead explor way file applic ahead result select geographi
seem like us gilead recogn price delay term
competit posit take step possibl acceler enrol compani
seem like provid updat trial time regulatori submiss first
half
final gilead report prep data descovi potenti offer life-cycl
extens truvada prep market current us patient approxim
recur revenue/year believ trial highli like succeed gilead
approxim year truvada patent expir switch commerci prep patient
truvada descovi although outsid us seem like prep use less
restrict gener truvada
leerink ep estim increas base tax margin improv pt base
result quarter manag commentari chang revenu
estim increas estim decreas
long-term forecast gilead product sale
guid rang estim suggest gilead total revenu declin
begin grow decreas total hcv
revenu forecast long-term also decreas total
hiv revenu forecast long-term revenu estim
consensu
ebit margin forecast percentag point higher percentag point
higher long-term reflect continu benefit compani care expens manag
later invest filgotinib commerci tax rate percentag point lower
rel stabl longer term result pro forma ep estim
increas ep estim
recent consensu base
chang revenu forecast ep estim cash flow chang peer
compani multipl decreas price target gilead maintain
market perform rate gilead stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap biopharma product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock celg
appli ep estim gilead give price altern
appli ex-growth large-cap medic product revenu
multipl revenu estim deriv impli valu impli
one year price target use sum part valuat exist franchis get
price consist primarili price compani hiv franchis
hcv product lastli dcf use forecast free cash flow
appli growth rate termin cash flow forecast discount valu back
present wacc give present valu averag four approach
price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv product
success develop underappreci element compani portfolio
selonsertib inhibitor fxr agonist inhibitor follow-on car-
indic stronger-than-expect convers current hiv patient gilead next
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit stock-
base compens
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
follow data
time
nash pbc psc
data atla
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
darunavir/c/f-taf royalti
darunavir/c/f-taf royalti
leerink partner research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
leerink revenu estim gilead
comp ex growth larg cap revenu multipl
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
leerink partner research compani file factset
